Contrasting Citius Oncology (CTOR) and Its Competitors

Citius Oncology (NASDAQ:CTOR) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Citius Oncology to similar companies based on the strength of its risk, dividends, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Citius Oncology and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	0	0	1.00
Citius Oncology Competitors	9789	15064	45328	1572	2.54

As a group, “Biotechnology” companies have a potential upside of 95.36%. Given Citius Oncology’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Citius Oncology has less favorable growth aspects than its competitors.

Profitability

This table compares Citius Oncology and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Citius Oncology Competitors	-9,046.59%	-199.78%	-30.61%

Insider & Institutional Ownership

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Citius Oncology and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Citius Oncology	N/A	-$24.76 million	-1.16
Citius Oncology Competitors	$691.14 million	$10.43 million	-10.08

Citius Oncology’s competitors have higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Citius Oncology has a beta of 3.56, indicating that its stock price is 256% more volatile than the S&P 500. Comparatively, Citius Oncology’s competitors have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.

Summary

Citius Oncology competitors beat Citius Oncology on 8 of the 13 factors compared.

Citius Oncology Company Profile

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.